EMG
STML

Ellington Management Group’s Stemline Therapeutics, Inc. STML Stock Holding History

Ellington Management Group’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-17,400
Closed -$160K – 945
2017
Q2 		$160K Buy
+17,400
New +$145K 0.02% 564

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ellington Management Group's STML Position: Q3 2017 in Review

Ellington Management Group sold out of Stemline Therapeutics, Inc. (STML) in Q3 2017, closing a stake of 17,400 shares — an estimated $160K sold.

Ellington Management Group first reported a position in STML in Q2 2017 and held it in 1 quarter. The position peaked at $160K in Q2 2017. 79 funds tracked by Wall St. Rank hold STML as of Q3 2017.

  • Ellington Management Group reported no remaining Stemline Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Ellington Management Group sold 17,400 Stemline Therapeutics, Inc. shares in Q3 2017, an estimated $160K.
  • Ellington Management Group first reported a position in Stemline Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
  • Ellington Management Group's Stemline Therapeutics, Inc. position peaked at $160K in Q2 2017.
  • 79 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2017.

Based on Ellington Management Group's 13F filing for Q3 2017, filed 14 Nov 2017.